Wegovy celebrates first birthday with subdued cheers

Novo Nordisk’s obesity drug Wegovy has had an eventful year. After getting off to a flying start, the firm hit a wall soon after launching when it became evident that demand far exceeded production capacity. Still, there’s light at the end of the tunnel, say two analysts.

Photo: Novo Nordisk / PR/Henning Larsen Architects

Almost exactly one year ago, on June 4, Denmark’s biggest pharmaceutical firm, Novo Nordisk, was granted approval by the US Food and Drug Administration (FDA) for the firm’s obesity drug, Wegovy.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today